| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
PBYI Stock Overview
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Rewards
Risk Analysis
Puma Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.27 |
| 52 Week High | US$7.84 |
| 52 Week Low | US$1.60 |
| Beta | 0.66 |
| 1 Month Change | 3.81% |
| 3 Month Change | 68.56% |
| 1 Year Change | -54.71% |
| 3 Year Change | -69.67% |
| 5 Year Change | -96.01% |
| Change since IPO | -75.78% |
Recent News & Updates
Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M
Puma Biotechnology press release (NASDAQ:PBYI): Q2 Non-GAAP EPS of $0.28. Revenue of $59.5M (+11.4% Y/Y). At June 30, 2022, Puma had cash, cash equivalents and marketable securities of $60.8M, compared to cash, cash equivalents and marketable securities of $82.1M at December 31, 2021.
Shareholder Returns
| PBYI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.4% | 1.4% | 3.6% |
| 1Y | -54.7% | -19.6% | -9.6% |
Return vs Industry: PBYI underperformed the US Biotechs industry which returned -19.6% over the past year.
Return vs Market: PBYI underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| PBYI volatility | |
|---|---|
| PBYI Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PBYI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: PBYI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 196 | Alan Auerbach | https://www.pumabiotechnology.com |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company’s drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd.
Puma Biotechnology, Inc. Fundamentals Summary
| PBYI fundamental statistics | |
|---|---|
| Market Cap | US$148.97m |
| Earnings (TTM) | -US$34.48m |
| Revenue (TTM) | US$206.86m |
0.7x
P/S Ratio-4.3x
P/E RatioIs PBYI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBYI income statement (TTM) | |
|---|---|
| Revenue | US$206.86m |
| Cost of Revenue | US$47.94m |
| Gross Profit | US$158.92m |
| Other Expenses | US$193.40m |
| Earnings | -US$34.48m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 76.83% |
| Net Profit Margin | -16.67% |
| Debt/Equity Ratio | 494.9% |
How did PBYI perform over the long term?
See historical performance and comparison